Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TMEM106B (E7H7Z) Rabbit Monoclonal Antibody #93334

Filter:
  • WB
  • IP
  • IHC
  • IF

    Product Specifications

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 42
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:50
    Immunofluorescence (Frozen) 1:100
    Immunofluorescence (Immunocytochemistry) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TMEM106B (E7H7Z) Rabbit Monoclonal Antibody recognizes endogenous levels of total TMEM106B protein. 93334 shows questionable staining in few tissues, including staining of a subset of cells among normal colon epithelium, squamous epithelium staining of one salivary tumor, and staining of cytoplasmic spots in one lymphoma.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala17 of human TMEM106B protein.

    Background

    Transmembrane protein 106B (TMEM106B) is a type II transmembrane protein with unknown function (1). TMEM106B was first identified as a major risk factor in genome-wide association studies in patients with frontotemporal lobar degeneration (FTLD), a neurodegenerative disorder characterized by atrophy in the frontal and temporal lobes of the brain (2). Localization of TMEM106B in late endosomal/lysosomal compartments suggests a role in regulating endo-lysosomal morphology and function (3). Endo-lysosomal dysfunction is likely a major cellular pathway that contributes to FTLD as other genetically linked FTLD genes, including C9orf72, GRN, and MAPT, converge on this cellular pathway (4). TMEM106B is sequentially processed through ectodomain shedding, followed by intramembrane proteolysis, with possible variability in the intramembrane cleavage site. Fragments consisting of residues 120–254 of TMEM106B have been shown to form amyloid filaments in human brains (5-7).

    Alternate Names

    FLJ11273; HLD16; MGC33727; T106B; TMEM106B; TMEM106B protein; Transmembrane protein 106B

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.